Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
| Route of Administration | Dosage Form / Strength | Clinically Relevant Non-medicinal Ingredients |
| Intravenous Injection | Lyophilized powder in following nominal strengths: 250 IU1/vial, 500 IU/vial, 1000 IU/vial, 2000 IU/vial | Mannitol, Polysorbate 80, Sucrose, Trisodium citrate. For a complete listing see Dosage Forms, Composition and Packaging. |
The number of units of FIX administered is expressed in International Units (IU), which are related to the current WHO standard for FIX products. One IU of FIX activity in plasma is equivalent to that quantity of FIX in one mL of normal human plasma. FIX activity in plasma is expressed either as a percentage (relative to normal human plasma) or in IU (relative to an International Standard for FIX in plasma).
IDELVION, Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP), is a long acting purified protein produced by recombinant DNA technology, generated by the genetic fusion of recombinant albumin to recombinant coagulation Factor IX (rFIX).
IDELVION is a preservative free, sterile, non-pyrogenic, lyophilized powder to be reconstituted with Sterile Water for Injection (SWFI) for intravenous injection. It is available in single-use vials in the following presentations: 250 IU, 500 IU, 1000 IU, and 2000 IU of the active substance rIX-FP.
Proper name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Chemical name: Albutrepenonacog Alfa
Molecular formula and molecular mass: Full length rIX-FP is expressed as a single chain glycopeptide of 1018 amino acids with a molecular weight of ~125 kDa.
Structural formula: The primary amino acid sequence is comparable to the most prevalent Thr148 allelic form of native FIX. rIX-FP was generated by the genetic fusion of recombinant human albumin to recombinant FIX. FIX complementary DNA (cDNA) was joined to human albumin cDNA by a FIX-derived cleavable linker sequence extended by an N-terminal proline residue.
 |
Physicochemical properties: The purified drug substance is a yellow to colorless solution that is visibly free of particulates. It is produced to have a minimum concentration of 8 mg/mL protein with a specific activity no less than 53 IU/mg.
IDELVION, Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP), is a long acting purified protein produced by recombinant DNA technology, generated by the genetic fusion of recombinant albumin to recombinant coagulation Factor IX (rFIX). The genetic fusion of the cDNA of human albumin to the cDNA of human coagulation Factor IX (FIX) enables the protein to be produced as a single recombinant protein and assures product homogeneity by avoiding chemical conjugation. The rFIX portion is identical to the Thr148 allelic form of plasma-derived FIX. The cleavable linker between the rFIX and albumin molecules is derived from the endogenous activation peptide in native FIX. rIX-FP remains intact in the circulation until FIX is activated, whereupon albumin is cleaved off, releasing activated FIX (FIXa) only when it is needed for coagulation.
No human or animal proteins are added during any stage of manufacturing or formulation of IDELVION. IDELVION is a glycoprotein consisting of 1018 amino acids secreted by a genetically engineered Chinese Hamster ovary (CHO) cell line. The CHO cell line secretes rIX-FP into a chemically defined, cell culture medium that does not contain hormones with the exception of recombinant human insulin, and the rIX-FP is purified by a chromatography purification process that does not require a monoclonal antibody step. The linker is derived from the actual activation peptide in native FIX. rIX-FP remains intact in the circulation until initiation of the coagulation cascade. The normal activation mechanism cleaves the albumin moiety simultaneously releasing albumin and activating FIX to facilitate coagulation. The manufacturing process includes two validated virus inactivation/removal steps, namely solvent/detergent treatment and nanofiltration.
The potency in International Units (IU) is determined using an in vitro activated partial thromboplastin time (aPTT)-based one-stage clotting assay calibrated against the World Health Organization (WHO) International Standard for FIX concentrate.
The manufacturing process has two dedicated, orthogonal virus reduction steps including nanofiltration.
IDELVION®, Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP), a recombinant DNA-derived coagulation Factor IX concentrate, is indicated in children and adults with Hemophilia B (congenital Factor IX deficiency) for:
IDELVION is not indicated for immune tolerance induction in patients with Hemophilia B.
For intravenous use after reconstitution only.
Required Units (IU) = Body Weight (kg) × Desired Factor IX rise (% of normal or IU/dL) × (reciprocal of recovery (IU/kg per IU/dL))
OR
Increase in Factor IX IU/dL (or % of normal) = Dose (IU) × Recovery (IU/dL per IU/kg)/body weight (kg)
A guide for dosing IDELVION for the on-demand treatment and control of bleeding episodes is provided in Table 1. Dosing should aim at maintaining a plasma Factor IX activity level at or above the plasma levels (in % of normal or IU/dL) outlined in Table 1.
Table 1: Dosing for On-demand Treatment and Control of Bleeding Episodes
| Type of Bleeding Episode | Circulating Factor IX Activity Required [% or (IU/dL)] | Frequency of Dosing (hours) | Duration of Therapy (days) |
| Minor or Moderate Uncomplicated hemarthrosis, muscle bleeding (except iliopsoas) or oral bleeding | 30-60 | 48-72 | At least 1 day, until bleeding stops and healing is achieved. Single dose should be sufficient for majority of bleeds. |
| Major Life or limb threatening hemorrhage, deep muscle bleeding, including iliopsoas, intracranial, retropharyngeal | 60-100 | 48-72 | 7-14 days, until bleeding stops and healing is achieved. Maintenance dose weekly. |
| * Adapted from the WFH Guidelines for the Management of Hemophilia. | |||
A guide for dosing IDELVION for perioperative management of bleeding is provided in Table 2.
Table 2: Dosing for Perioperative Management of Bleeding
| Type of Surgery | Circulating Factor IX Activity Required [% or (IU/dL)] | Frequency of Dosing (hours) | Duration of Therapy (days)* |
| Minor (including uncomplicated tooth extraction) | 50-80 | 48-72 | At least 1 day, or until healing is achieved. Single dose should be sufficient for a majority of minor surgeries. |
| Major (including intracranial, pharyngeal, retropharyngeal, retroperitoneal) | 60-100 (initial level) | 48-72 | 7-14 days, or until bleeding stops and healing is achieved. Repeat dose every 48-72 hours for the first week or until healing is achieved. Maintenance dose 1-2 times per week. |
| * Adapted from the WFH Guidelines for the Management of Hemophilia. | |||
For patients ≥12 years of age, the recommended dose is 25-40 IU IDELVION per kg body weight every 7 days. Patients who are well-controlled on a 7- day regimen may be switched to a 14-day interval at 50-75 IU IDELVION per kg body weight [see Clinical Studies].
For patients <12 years of age, the recommended dose is 40-55 IU IDELVION per kg body weight every 7 days.
The procedures below are provided as general guidelines for the preparation and reconstitution of IDELVION.
IDELVION Reconstitution Instructions
1. Place the IDELVION vial, diluent vial, and Mix2Vial transfer set on a flat surface.
2. Remove flip caps from the IDELVION and Sterile Water for Injection (diluent) vials.
3. Wipe the stoppers with the sterile alcohol swab provided and allow to dry prior to opening the Mix2Vial transfer set package.
4. Open the Mix2Vial transfer set package by peeling away the lid (Fig. 1). Do not remove the device from the package.
Figure 1
 |
5. Place the diluent vial on a flat surface and hold the vial tightly. Grip the Mix2Vial transfer set together with the clear package and push the plasticspike at the blue end of the Mix2Vial transfer set firmly through the center of the stopper of the diluent vial (Fig. 2).
Figure 2
![IDELVION [Coagulation Factor IX (Recombinant), Albumin Fusion Protein]
Lyophilized Powder for Solution for Intravenous Injection Structural Formula - Illustration](https://images.rxlist.com/images/rxlist/idelvion2.gif) |
6. Carefully remove the clear package from the Mix2Vial transfer set. Do not remove the Mix2Vial transfer set or touch the exposed end of the device (Fig. 3).
Figure 3
 |
7. With the IDELVION vial placed firmly on a flat surface, invert the diluent vial with the Mix2Vial transfer set attached and push the plastic spike of the transparent adapter firmly through the center of the stopper of the IDELVION vial (Fig. 4). The diluent will automatically transfer into the IDELVION vial.
Figure 4
 |
8. With the diluent and IDELVION vial still attached to the Mix2Vial transfer set, gently swirl the IDELVION vial to ensure that the powder is fully dissolved (Fig. 5). Do not shake the vial.
Figure 5
 |
9. With one hand, grasp the IDELVION side of the Mix2Vial transfer set and with the other hand grasp the blue diluent-side of the Mix2Vial transfer set, and unscrew the set into two pieces (Fig. 6).
Figure 6
 |
10. Draw air into an empty, sterile syringe. While the IDELVION vial is upright, screw the syringe to the Mix2Vial transfer set. Inject air into the IDELVION vial.
11. While keeping the syringe plunger pressed, invert the system upside down and draw the concentrate into the syringe by pulling the plunger back slowly (Fig. 7).
Figure 7
 |
12. Disconnect the filled syringe by unscrewing it from the Mix2Vial transfer set (Fig. 8). The reconstituted solution should be a clear or yellow to colorless solution. Do not use if particulate matter or discoloration is observed.
Figure 8
 |
13. Use immediately or within 4 hours of reconstitution. Store reconstituted solution at room temperature. Do not refrigerate.
14. If the dose requires more than one vial, use a separate, unused Mix2Vial transfer set and Sterile Water for Injection (diluent) vial for each product vial. Repeat steps 10-12 to pool the contents of the vials into one syringe.
For intravenous injection only.
IDELVION is a pale yellow to white lyophilized powder supplied in single-dose vials containing nominally 250, 500, 1000, 2000, or 3500 IU of Factor IX potency. The actual factor IX potency is labeled on each vial and carton.
IDELVION is supplied as a lyophilized powder in single-dose vials containing the labeled amount of Factor IX activity, expressed in international units (IU).
IDELVION is packaged with 2.5 mL (for reconstitution of 250, 500 or 1000 IU vials) or 5 mL (for reconstitution of 2000 or 3500 IU vials) of Sterile Water for Injection, USP, one Mix2Vial filter transfer set, and one sterile alcohol swab. Components are not made with natural rubber latex.
Table 9: How Supplied
| Nominal Strength (International LTnits) | Fill Size Color Indicator | Kit NDC |
| 250 | Orange | 69911-864-02 |
| 500 | Blue | 69911-865-02 |
| 1000 | Green | 69911-866-02 |
| 2000 | Purple | 69911-867-02 |
| 3500 | Yellow | 69911-869-02 |
Manufactured by: CSL Behring GmbH, 35041 Marburg, Germany. for: CSL Behring Lengnau AG, Biotech Innovation Park, 2543 Lengnau, Switzerland, US License No. 2009. Distributed by: CSL Behring LLC, Kankakee, IL 60901 USA. Revised: Jul 2021
The most common adverse reactions (incidence ≥1%) reported in clinical trials were headache and dizziness.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.
In five multicenter, prospective, open-label clinical trials with IDELVION, 114 previously treated patients (PTPs; exposed to a Factor IX-containing product for ≥100 exposure days) received at least one infusion of IDELVION as part of on-demand treatment of bleeding episodes, perioperative management of major and minor surgical, dental, or other invasive procedures, routine prophylaxis, or pharmacokinetic evaluation. Twenty-seven children were <12 years of age, 9 adolescents were 12 to <18 years of age, and 78 adults were ≥18 to ≤65 years of age. A total of 16,326 injections were administered over a median of 1,543.5 days (range: 25 to 2,565 days).
Adverse reactions that occurred in >0.5% of subjects are listed in Table 3.
Table 3: Summary of Adverse Reactions
| MedDRA Standard System Organ Class | Adverse Reaction | Number of subjects n (%), (N=114) |
| Nervous system disorders | Headache | 2 (1.8) |
| Dizziness | 2 (1.8) | |
| Immune system disorders | Hypersen siti vity | 1 (0.9) |
| Skin and subcutaneous tissue disorders | Rash | 1 (0.9) |
| Eczema | 1 (0.9) |
All subjects were monitored for inhibitory and binding antibodies to rIX-FP (specifically rFIX, pdFIX and albumin), and binding antibodies to CHO host cell proteins at the following time points: at screening, at 2-4 weeks, 12 weeks following the first infusion of IDELVION, every 3 months thereafter (every 6 months for binding antibodies in children). No subjects developed antibodies to Factor IX, or non-neutralizing antibodies against factor IX, albumin and CHO protein at any of the time points following infusion of IDELVION.
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, it may be misleading to compare the incidence of antibodies to IDELVION in the studies described above with the incidence of antibodies in other studies or to other products.
The following adverse reaction has been identified during post-approval use of IDELVION. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Blood and lymphatic system disorders: Factor IX inhibitor development
No Information provided
Included as part of the PRECAUTIONS section.
Hypersensitivity reactions, including anaphylaxis, are possible. Early signs of hypersensitivity reactions, which can progress to anaphylaxis include angioedema, chest tightness, hypotension, generalized urticaria, wheezing, and dyspnea. If hypersensitivity symptoms occur, immediately discontinue administration and initiate appropriate treatment.
IDELVION contains trace amounts of Chinese hamster ovary (CHO) proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins.
The formation of neutralizing antibodies (inhibitors) to Factor IX has been reported with IDELVION [see ADVERSE REACTIONS]. Monitor all patients treated with IDELVION for the development of neutralizing antibodies (inhibitors) by appropriate clinical observations or laboratory tests. Perform an assay that measures Factor IX inhibitor concentration if expected plasma Factor IX activity levels are not attained, or if the bleeding is not controlled with an appropriate dose.
Patients with Factor IX inhibitors are at an increased risk of severe hypersensitivity reactions or anaphylaxis if re-exposed to Factor IX. Evaluate patients experiencing allergic reactions for the presence of an inhibitor and closely monitor patients with inhibitors for signs and symptoms of acute hypersensitivity reactions, particularly during early phases of exposure to the product [see WARNINGS AND PRECAUTIONS].
Thromboembolism (e.g., pulmonary embolism, venous thrombosis, and arterial thrombosis) may occur when using Factor IX-containing products. Because of the potential risk for thromboembolism with the use of Factor IX products, monitor for early signs of thromboembolism and consumptive coagulopathy when administering IDELVION to patients with liver disease, fibrinolysis, perioperative status, or risk factors for thromboembolic events or disseminated intravascular coagulation.
Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with Factor IX inhibitors and a history of allergic reactions. The safety and efficacy of using IDELVION for immune tolerance induction have not been established.
Nonclinical studies evaluating the carcinogenic potential of IDELVION have not been conducted.
No macroscopic or microscopic pathologies in reproductive organs were observed in animals dosed every day for 28 days with 6.7 times the maximum recommended prophylactic clinical dose of 75 IU/kg IDELVION. No animal studies regarding impairment of fertility following IDELVION dosing were conducted.
There are no data with IDELVION use in pregnant women to inform on drug-associated risk. Animal reproduction studies have not been conducted using IDELVION. It is not known whether IDELVION can cause fetal harm or affect reproduction capacity when administered to a pregnant woman. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
There is no information regarding the excretion of IDELVION in human milk, the effect on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for IDELVION and any potential adverse effects on the breastfed infant from IDELVION or from the underlying maternal condition.
In clinical studies that included 34 subjects <18 years old, the prophylactic administration with IDELVION every 7 days was successful in prevention of spontaneous bleeding episodes requiring treatment [see Clinical Studies]. Of these, 7 subjects were ≥12 and <18 years old; 5 of these subjects switched to a 10- or 14-day prophylactic administration with IDELVION. There were no apparent differences in the safety profile in subjects <18 years as compared to adults [see ADVERSE REACTIONS].
Compared to adults, incremental rIX-FP recovery appeared to be slightly lower and body weight-adjusted clearance appeared to be higher. Children may have higher Factor IX body weight-adjusted clearance, shorter half-life, and lower recovery. Higher dose per kilogram body weight or more frequent dosing may be needed in these patients [see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY].
Clinical studies of IDELVION did not include subjects over 65 years to determine whether or not they respond differently from younger subjects.
REFERENCES
1. Wilmot HV, Hogwood J, Gray E. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays. Haemophilia 2014, 1-7.
2. Fritsma GA, Dembitzer FR, Randhawa A, et al. Recommendations for Appropriate Activated Partial Thromboplastin Time Reagent Selection and Utilization. Am J Clin Pathol 2012;137:904-908.
3. Sommer JM, Buyue Y, Bardan S, Peters RT, Jiang H, Kamphaus G, Gray E, Pierce GF. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. Thrombosis and Haemostasis 2014, 112(5):932-40.
No Information provided
IDELVION is contraindicated in patients who have had life-threatening hypersensitivity reactions to IDELVION, or its components, including hamster proteins [see WARNINGS AND PRECAUTIONS].
IDELVION is a recombinant protein that temporarily replaces the missing coagulation Factor IX needed for effective hemostasis. IDELVION is comprised of genetically fused recombinant coagulation Factor IX and recombinant albumin. Fusion with recombinant albumin extends the half-life of Factor IX [see DESCRIPTION and CLINICAL PHARMACOLOGY].
The administration of IDELVION increases plasma levels of Factor IX and can temporarily correct the coagulation defect in patients.
The pharmacokinetic (PK) profiles of IDELVION were evaluated following intravenous injections of single doses of 25, 50 or 75 IU/kg. The PK parameters were based on plasma Factor IX activity measured by the one-stage clotting assay. Blood samples for PK analysis were collected prior to dosing and up to 336 hours (14 days) after dosing.
Table 4 provides the pharmacokinetic parameters following a single 25 IU/kg, 50 IU/kg, or 75 IU/kg dose of IDELVION.
Table 4: Pharmacokinetic Parameters (Arithmetic Mean, CV%) Following a Single 25 IU/kg, 50 IU/kg, or 75 IU/kg Dose of IDELVION
| PK Parameters | rlX-FP 25 (IU/kg) (N=7) |
rlX-FP 50 (IU/kg) (N=47) |
rlX-FP 75 (IU/kg) (N=8) |
| IR (IU/dL)/(IU/kg) | 1.65 (11) | 1.30 (24) | 1.08 (20) |
| Cmax (IU/dL) | 41.1 (13) | 66.6 (27) | 82.0 (20) |
| AUC0-inf (h*IU/dL) | 4658 (36) | 7482 (28) | 9345 (20) |
| t½ (hours) | 118(38) | 104 (25) | 104(18) |
| MRT (hours) | 153 (24) | 143 (23) | 145 (14) |
| CL (mL/h/kg) | 0.57 (31) | 0.73 (27) | 0.84 (20) |
| Vss (dL/kg) | 0.86 (32) | 1.02 (28) | 1.20 (23) |
| Time to 1% Factor IX Activity (days)* | 22 (25) | 23 (19) | 25(13) |
| Time to 3% Factor IX Activity (days)* | 14 (19) | 17(19) | 18(13) |
| Time to 5% Factor IX Activity (days)* | 10 (25) | 13 (20) | 15(13) |
| IR = incremental recovery recorded 30 minutes after injection; AUC = area under the Factor IX activity time curve; t = half-life; MRT = mean residence time; CL = body weight adjusted clearance; Vss = body weight adjusted volume of distribution at steady-state. * = Estimated time to mean Factor IX activity maintained above the pre-specified percent (%) |
|||
IDELVION PK parameters following single or repeat dosing for up to 30 weeks were similar.
Pharmacokinetic parameters of IDELVION were evaluated in 5 adolescents (12 to <18 years of age) and 27 children (0 to <12 years of age) in open-label, multi-center studies following a 50 IU/kg intravenous injection of IDELVION. The PK samples were collected prior to dosing and at multiple time points up to 336 hours (14 days) after dosing.
Table 5 summarizes the PK parameters calculated from the pediatric data of 32 subjects, 0 to <18 years of age. The parameters estimated were based on the plasma Factor IX activity over time profile. Compared to adults, incremental recovery is lower (15% to 27%) and body weight-adjusted clearance is higher (45% to 62%) in children.
Table 5: Pharmacokinetic Parameters (Arithmetic Mean, CV%) of IDELVION Following a Single 50 IU/kg Dose
| PK Parameters | 0 to <6 years (N=12) |
6 to <12 years (N=15) |
12 to <18 years (N=5) |
| IR (IU/dL)/(IU/kg) | 0.95 (22) | 1.06 (23) | 1.11 (28) |
| Cmax (IU/dL) | 48.3 (19) | 52.9 (23) | 55.3 (28) |
| AUC0-inf (h*IU/dL) | 4583 (33) | 5123 (31) | 5347 (48) |
| t½ (hours) | 90 (13) | 93 (21) | 87 (36) |
| MRT (hours) | 123 (14) | 129 (19) | 119 (31) |
| CL (mL/h/kg) | 1.18(28) | 1.06 (29) | 1.08 (39) |
| Vss (dL/kg) | 1.42 (24) | 1.32 (20) | 1.16 (14) |
| Time to 1% Factor IX Activity (days) * | 17 (29) | 20 (22) | 19 (37) |
| Time to 3% Factor IX Activity (days) * | 12 (32) | 14 (22) | 13 (38) |
| Time to 5% Factor IX Activity (days) * | 9 (32) | 11(26) | 11 (38) |
| IR = incremental recovery recorded 30 minutes after injection; AUC = area under the Factor IX activity time curve; t = half-life; MRT = mean residence time; CL = body weight adjusted clearance; Vss = body weight adjusted volume of distribution at steady-state. *= Estimated time to mean Factor IX activity maintained above the pre-specified percent (%) |
|||
The safety and efficacy of IDELVION were evaluated in a prospective, open-label, multicenter clinical study of 63 male previously treated patients (PTPs) with hemophilia B (≤2% endogenous Factor IX activity) who received at least one infusion of IDELVION as part of on-demand treatment and control of bleeding episodes, perioperative management of major and minor surgical, dental, or other invasive procedures, routine prophylaxis once every 7-, 10- or 14-day intervals, or pharmacokinetic evaluation. Subjects were aged 12 to 61 years; including 7 adolescent subjects aged 12 to 17. Subjects were treated for up to 27 months.
A total of 358 bleeding events were treated with IDELVION. Among them, 204 (57%) bleeding events were spontaneous, 140 (39%) events were traumatic and 14 (4%) events were unknown. In addition, a total of 267 (75%) episodes were joint bleeding events.
Overall treatment efficacy was assessed for each bleeding episode by the investigator based on a 4-point scale of excellent, good, moderate, or poor/no response. The efficacy of IDELVION for the on-demand treatment and control of bleeding episodes is summarized in Table 6.
Table 6: Efficacy of IDELVION for the On-demand Treatment and Control of Bleeding Episodes
| Number of Bleeding Episodes Requiring Treatment (n = 358) | |
| Number of injections to treat bleeding episodes | |
| 1 injection, n (%) | 335 (94) |
| 2 injections, n (%) | 18 (5) |
| >2 injections, n (%) | 5 (1.4) |
| Assessment of Efficacy* | |
| Excellent or Good, n (%) | 337 (94) |
| Moderate, n (%) | 9 (2.5) |
| Poor/no response, n (%) | 1 (0.3) |
| *Excellent: Pain relief and/or unequivocal improvement in objective signs of bleeding and no additional infusion required in order to achieve hemostasis; Good: Definite pain relief and/or improvement in signs of bleeding at approximately 8 hours after the first infusion, but may require a second infusion; Moderate: Probable or slight beneficial effect, and requires more than two infusions to achieve hemostasis; Poor/no response: No improvement at all or condition worsens, additional hemostatic intervention is required. Responses evaluated at approximately 24 hours after treatment. | |
In the two effectiveness studies and the extension study, a total of 20 subjects (5-59 years of age) received IDELVION for perioperative management of 29 surgical procedures. Dose was individualized based on subject's PK and clinical response to treatment. These included orthopedic surgeries (n=14), a mastectomy with liposuction (n=1), a hemorrhoidectomy (n=2), rhinoplasty, submucosal resection and inferior turbinectomy (n=1), circumcision (n=3), tooth extractions (n=5), embolism of scrotal variocele (n=1), excision of pigmented nevus (n=1) and endoscopic mucosal resection (n=1).
A single preoperative bolus was used in 97% (n=28) of surgeries. Hemostatic efficacy was rated as excellent or good for all surgeries at all time points for which hemostatic response was reported, except for one evaluation that was rated moderate at the 48-hour assessment. During the 14-day postoperative period, patients received between 0 and 11 infusions and FIX consumption was between 0 and 444.1 IU/kg. Six patients undergoing surgery were discharged from the surgical treatment site on the same day.
Of the 63 subjects treated with IDELVION, twenty-three PTPs received IDELVION only for the treatment of bleeding episodes during the first 6 months of the study. Nineteen of these PTPs switched to once weekly prophylaxis with additional median duration of 10 months.
Based on the analysis of the 19 subjects treated with IDELVION for on-demand therapy and weekly prophylaxis, the median annualized spontaneous bleeding rate (AsBR) during prophylaxis treatment was 0.7 (range: 0 to 4.2), as compared to 15.4 (range: 2 to 39.5) during on-demand treatment. Based on the Poisson model, prophylaxis treatment with IDELVION resulted in a 93% reduction in the annualized spontaneous bleeding rate.
The median annualized bleeding rate (total ABR – spontaneous and traumatic) during prophylaxis treatment was 1.6; (range: 0 to 21.1), as compared to 19.2; (range: 2 to 46.1) during on-demand treatment. Based on the Poisson model, prophylaxis treatment with IDELVION resulted in an 88% reduction in the annualized bleeding rate.
Table 7: Comparison of Annualized Bleeding Rates for Subjects Treated for On-demand Therapy and Weekly Prophylaxis
| Bleeding Episode Etiology | On-demand (n=19) |
Weekly Prophylaxis (n=19)* |
Percent Reduction with Prophylaxis (n=19)* |
| Spontaneous | |||
| Mean (SD) | 14.6 (8.42) | 0.9 (1.17) | 93.5 (8.03) |
| Median | 15.4 | 0.7 | 95.9 |
| IQR | 8.0. 18.0 | 0. 1.6 | 89.0. 100 |
| Range | 2.0, 39.5 | 0,4.2 | 75.2, 100 |
| Total† | |||
| Mean (SD) | 20.8 (9.19) | 2.9 (4.79) | 88.0 (14.06) |
| Median | 19.2 | 1.6 | 90.9 |
| IQR | 16.7. 25.8 | 0. 4.3 | 81.2. 100 |
| Range | 2.0,46.1 | 0,21.1 | 54.3, 100 |
| IQR=interquartile range, defined for 25 percentile and 75 percentile; SD=standard deviation; Subjects evaluable for efficacy are subjects who received at least one dose of on-demand treatment, and one dose of prophylaxis treatment. *Based on matched pairs design †Total includes spontaneous and traumatic bleeds |
|||
Forty subjects received weekly routine prophylaxis. Thirty-seven subjects completed 6 months of once weekly prophylaxis. Of these, 21 subjects switched to a 14-day interval with 50-75 IU/kg of IDELVION with a median duration of 12.7 months. Prior to switching, these 21 subjects were well controlled with IDELVION (did not require dose adjustments or experience spontaneous bleeding 1 month prior to switch and were maintained on a prophylaxis dose of ≤40 IU/kg every 7 days).
The median AsBRs for the 21 subjects treated with weekly and 14-day prophylaxis were zero (range: 0 to 4.5) and zero (range: 0 to 7.3), respectively (summarized in Table 8). In addition, the median AsBRs for the 7 subjects treated with weekly and 10-day prophylaxis were zero (range: 0 to 0) and zero (range: 0 to 0.9), respectively.
Table 8: Comparison of Annualized Spontaneous Bleeding Rate (AsBR) by Prophylaxis Regimen for Subjects in the Clinical Trial
| Bleeding Episode Etiology | Weekly Prophylaxis (11=21)* |
14-day Prophylaxis (11=21)* |
| Spontaneous | ||
| Mean (SD) | 0.28 (1.01) | 1.07 (2.1) |
| Median | 0 | 0 |
| IQR | 0.0 | 0. 1 |
| Range | 0.4.5 | 0. 7.3 |
| IQR = interquartile range; SD = Standard deviation *Based on a matched pairs design |
||
Safety, efficacy, and pharmacokinetics of IDELVION have been evaluated in previously treated pediatric patients (PTPs) ranging from one (1) to <12 years of age. A total of 27 males, 12 patients <6 years of age and 15 patients between 6 to <12 years of age, received IDELVION for prophylaxis and control of bleeding episodes. All 27 subjects received weekly prophylaxis treatment with IDELVION for a mean time on study of 13.1 months (range: 9, 18 months).
The routine weekly regimen with rIX-FP was effective in the prophylaxis of bleeding episodes. The median (Q1, Q3) ABR (total bleeding episodes, including untreated) and annualized spontaneous bleeding rate (AsBR) during prophylaxis treatment in the efficacy population were 3.41 [1.18,7.44] and 0 [0, 1.34] bleeding episodes/subject/year, respectively. The mean ABR was 4.55 bleeding episodes/year/subject and the mean AsBR was 0.79 based on the total of both treated and untreated bleeding episodes. The target joints (defined as 3 or more spontaneous bleeds into a single joint within a consecutive 6-months period) reported in 3 subjects prior to study entry were resolved during the study. All subjects maintained a weekly routine prophylaxis regimen throughout.
Of the 106 bleeding episodes, the majority (94;89%) was treated with single injection, 103 (97%) were treated with 1-2 injections. Hemostatic efficacy at resolution of a bleed was rated excellent or good in 96% of all treated bleeding episodes.
IDELVION®
(eye del' vee on),
Coagulation Factor IX (Recombinant), Albumin Fusion Protein
This leaflet summarizes important information about IDELVION. Please read it carefully before using IDELVION. This information does not take the place of talking with your healthcare provider, and it does not include all of the important information about IDELVION. If you have any questions after reading this, ask your healthcare provider.
What is IDELVION?
IDELVION, Coagulation Factor IX (Recombinant), Albumin Fusion Protein is an injectable medicine used to replace clotting factor (Factor IX) that is missing in people with hemophilia B (also called congenital Factor IX deficiency or Christmas disease). Hemophilia B is an inherited bleeding disorder that prevents blood from clotting normally. IDELVION is used in children and adults with hemophilia B to control and prevent bleeding episodes. Your healthcare provider may give you IDELVION when you have surgery. IDELVION can reduce the number of bleeding episodes when used regularly (prophylaxis).
Who should not use IDELVION?
You should not use IDELVION if you:
Tell your healthcare provider if you have had an allergic reaction to any Factor IX product prior to using IDELVION.
Tell your healthcare provider if you are pregnant or breast-feeding because IDELVION may not be right for you.
What should I tell my healthcare provider before using IDELVION?
You should tell your healthcare provider if you:
How should I administer IDELVION?
What are the possible side effects of IDELVION?
Allergic reactions may occur with IDELVION. Call your healthcare provider right away and stop treatment if you get a rash or hives, itching, tightness of the chest or throat, difficulty breathing, light-headedness, dizziness, nausea, or decrease in blood pressure.
Your body can make antibodies, called inhibitors, against Factor IX which may stop IDELVION from working properly. Your healthcare provider may need to test your blood for inhibitors from time to time.
IDELVION may increase the risk of forming abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider if you have chest pain, difficulty breathing, leg tenderness or swelling.
The most common side effects of IDELVION are headache and dizziness.
This is not the only side effect possible with IDELVION. To learn more, talk to your healthcare provider or pharmacist. Tell your healthcare provider about any side effect that bothers you or does not go away.
What are the IDELVION dosage strengths?
IDELVION comes in five different dosage strengths: 250, 500, 1000, 2000, or 3500 IU. The actual strength of IDELVION is printed on the carton and vial label. The labeling of the five dosage strengths are color-coded as provided in Table 1 below.
Table 1: IDELVION Dosage Strengths
| Fill Size Color Indicator | Nominal Strength |
| Orange | 250 IU |
| Blue | 500 IU |
| Green | 1000 IU |
| Purple | 2000 IU |
| Yellow | 3500 IU |
Always check the actual dosage strength printed on the label to make sure you are using the strength prescribed by your healthcare provider.
How should I store IDELVION?
What else should I know about IDELVION?
Instructions for Use
For intravenous use after reconstitution only.
Do not attempt to do an intravenous injection unless you have been taught how by your healthcare provider or hemophilia center.
Always follow the specific instructions given by your healthcare provider. The steps listed below are general guidelines for using IDELVION. If you are unsure of the instructions, call your healthcare provider before using IDELVION. Call your healthcare provider right away if bleeding is not controlled after using IDELVION. Your healthcare provider will prescribe the dose that you should take. You may need to have blood tests from time to time. Talk to your healthcare provider before traveling. Dispose of all unused solution, empty vial(s), and other used medical supplies in an appropriate medical waste container.
IDELVION Reconstitution Instructions
1. Place the IDELVION vial, diluent vial, and Mix2Vial® transfer set on a flat surface.
2. Remove flip caps from the IDELVION and Sterile Water for Injection (diluent) vials.
3. Wipe the stoppers with the sterile alcohol swab provided and allow to dry prior to opening the Mix2Vial transfer set package.
4. Open the Mix2Vial transfer set package by peeling away the lid (Fig. 1). Do not remove the device from the package.
Figure 1
|
5. Place the diluent vial on a flat surface and hold the vial tightly. Grip the Mix2Vial transfer set together with the clear package and push the plastic spike at the blue end of the Mix2Vial transfer set firmly through the center of the stopper of the diluent vial (Fig. 2).
Figure 2
 |
6. Carefully remove the clear package from the Mix2Vial transfer set. Do not remove the Mix2Vial transfer set or touch the exposed end of the device (Fig. 3).
Figure 3
 |
7. With the IDELVION vial placed firmly on a flat surface, invert the diluent vial with the Mix2Vial transfer set attached and push the plastic spike of the transparent adapter firmly through the center of the stopper of the IDELVION vial (Fig. 4). The diluent will automatically transfer into the IDELVION vial.
Figure 4
 |
8. With the diluent and IDELVION vial still attached to the Mix2Vial transfer set, gently swirl the IDELVION vial to ensure that the powder is fully dissolved (Fig. 5). Do not shake the vial.
Figure 5
 |
9. With one hand, grasp the IDELVION side of the Mix2Vial transfer set and with the other hand grasp the blue diluent-side of the Mix2Vial transfer set, and unscrew the set into two pieces (Fig. 6).
Figure 6
 |
10. Draw air into an empty, sterile syringe. While the IDELVION vial is upright, screw the syringe to the Mix2Vial transfer set. Inject air into the IDELVION vial.
11. While keeping the syringe plunger pressed, invert the system upside down and draw the concentrate into the syringe by pulling the plunger back slowly (Fig. 7).
Figure 7
 |
12. Disconnect the filled syringe by unscrewing it from the Mix2Vial transfer set (Fig. 8). The reconstituted solution should be a clear or yellow to colorless solution. Do not use if particulate matter or discoloration is observed.
Figure 8
 |
13. Use immediately or within 4 hours of reconstitution. Keep solution at room temperature. Do not refrigerate after reconstitution.
14. If the dose requires more than one vial, use a separate, unused Mix2Vial transfer set and Sterile Water for Injection (diluent) vial for each product vial. Repeat steps 10-12 to pool the contents of the vials into one syringe.
15. Record treatment – Remove the peel-off portion of the label from each vial used and affix it to the patient's treatment diary/log book.
Administration (intravenous injection)
Resources at CSL Behring available to the patient:
For Adverse Reaction Reporting contact:
CSL Behring Pharmacovigilance Department at 1-866-915-6958
Contact CSL Behring to receive more product information:
Patient Support Hotline at 1-800-676-4266
